**TransThera Sciences (Nanjing), Inc.**
**藥捷安康（南京）科技股份有限公司**
*(A joint stock company incorporated in the People's Republic of China with limited liability)*
**(Stock Code: 2617)**

# POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 4 AUGUST 2025

The Board is pleased to announce that all proposed resolutions were duly passed by the Shareholders by way of poll at the AGM held on 4 August 2025.

References are made to the notice of the annual general meeting (the "**Notice**") and the circular (the "**Circular**") of TransThera Sciences (Nanjing), Inc. (the "**Company**") both dated 11 July 2025. Unless stated otherwise, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

The Board is pleased to announce that all proposed resolutions as set out in the Notice were duly passed by the Shareholders at the AGM by way of poll.

As at the date of the AGM, the total number of issued Shares of the Company was 396,897,633 Shares, of which 301,666,673 Shares were H Shares and 95,230,960 Shares were Unlisted Shares. All Shares entitled the holders to attend the AGM and vote on the resolutions proposed at the AGM.

No Shareholder was required under the Listing Rules to abstain from voting on the proposed resolutions at the AGM. There were no Shares entitling the Shareholders to attend the AGM but abstain from voting in favour of the proposed resolutions at the AGM under Rule 13.40 of the Listing Rules. None of the Shareholders have stated his, her or its intention in the Circular to vote against or to abstain from voting on the resolutions at the AGM.

Tricor Investor Services Limited, the H share registrar of the Company acted as the scrutineers for the vote-taking at the AGM.

All directors and all supervisors of the Company attended the AGM.

The poll results in respect of all proposed resolutions at the AGM were as follows:

| ORDINARY RESOLUTIONS | | Number of Votes (%) | | |
|---|---|---|---|---|
| | | **FOR** | **AGAINST** | **ABSTAIN** |
| 1. | To consider and approve the resolution on the 2024 work report of the board of directors (the "**Board**") of the Company. | 321,419,950 (99.99%) | 0 (0.00%) | 25,000 (0.01%) |
| 2. | To consider and approve the resolution on the 2024 work report of the supervisory committee ("**Supervisory Committee**") of the Company. | 323,914,319 (99.99%) | 0 (0.00%) | 25,000 (0.01%) |
| 3. | To consider and approve the resolution on the 2024 financial report of the Company. | 321,419,950 (99.99%) | 0 (0.00%) | 25,000 (0.01%) |
| 4. | To consider and approve the resolution on the uncovered losses amounting to one-third of the total paid-up share capital. | 323,914,319 (99.99%) | 0 (0.00%) | 25,000 (0.01%) |
| 5. | To consider and approve the resolution on the 2024 profit distribution plan of the Company. | 323,914,319 (99.99%) | 0 (0.00%) | 25,000 (0.01%) |
| 6. | To consider and approve the resolution on the appointment of Ernst & Young as auditor of the Company for 2025, and to authorize the Board to fix its remuneration. | 323,914,319 (99.99%) | 0 (0.00%) | 25,000 (0.01%) |
| 7. | To consider and approve the resolution on the remuneration plan for directors ("**Director(s)**") of the Company for 2025. | 323,914,319 (99.99%) | 0 (0.00%) | 25,000 (0.01%) |
| 8. | To consider and approve the resolution on the remuneration plan for supervisors ("**Supervisor(s)**") of the Company for 2025. | 323,914,319 (99.99%) | 0 (0.00%) | 25,000 (0.01%) |
| 9. | To consider and approve the election of Directors of the second session of the Board. | | | |
| | (1) To elect Dr. Frank Wu as executive Director of the second session of the Board. | 323,914,319 (99.99%) | 0 (0.00%) | 25,000 (0.01%) |
| | (2) To elect Mr. Wu Di as executive Director of the second session of the Board. | 323,914,319 (99.99%) | 0 (0.00%) | 25,000 (0.01%) |
| | (3) To elect Ms. Jia Zhongxin as non-executive Director of the second session of the Board. | 321,669,386 (99.99%) | 0 (0.00%) | 25,000 (0.01%) |

| ORDINARY RESOLUTIONS | | Number of Votes (%) | | |
|---|---|---|---|---|
| | | FOR | AGAINST | ABSTAIN |
| | (4) To elect Dr. Yi Hua as non-executive Director of the second session of the Board. | 301,807,072 (99.99%) | 0 (0.00%) | 25,000 (0.01%) |
| | (5) To elect Ms. Chui Hoi Yam as independent non-executive Director of the second session of the Board. | 301,807,072 (99.99%) | 0 (0.00%) | 25,000 (0.01%) |
| | (6) To elect Ms. Zheng Zhelan as independent non-executive Director of the second session of the Board. | 299,562,139 (99.99%) | 0 (0.00%) | 25,000 (0.01%) |
| | (7) To elect Mr. Li Shu Pai as independent non-executive Director of the second session of the Board. | 301,807,072 (99.99%) | 0 (0.00%) | 25,000 (0.01%) |
| 10. | To consider and approve the election of shareholder representative Supervisors of the second session of the Supervisory Committee. | | | |
| | (1) To elect Mr. Mei Jianghua as a shareholder representative Supervisor of the second session of the Supervisory Committee. | 323,914,319 (99.99%) | 0 (0.00%) | 25,000 (0.01%) |
| | (2) To elect Ms. Pang Yajing as a shareholder representative Supervisor of the second session of the Supervisory Committee. | 323,914,319 (99.99%) | 0 (0.00%) | 25,000 (0.01%) |

| SPECIAL RESOLUTIONS | | Number of Votes (%) | | |
|---|---|---|---|---|
| | | FOR | AGAINST | ABSTAIN |
| 11. | To grant a general mandate to the Directors to allot, issue and deal with (including sale or transfer of any treasury shares) additional Shares (details of this resolution were set out in the notice of AGM dated 11 July 2025). | 301,781,029 (93.81%) | 16,231,317 (5.05%) | 3,682,040 (1.14%) |
| 12. | To grant a general mandate to the Directors to repurchase H Shares (details of this resolution were set out in the notice of AGM dated 11 July 2025). | 323,914,319 (99.99%) | 0 (0.00%) | 25,000 (0.01%) |
| 13. | To extend the general mandate granted under resolution no. 11 by adding the Shares repurchased pursuant to the general mandate granted by resolution no. 12. | 304,025,962 (93.85%) | 16,231,317 (5.01%) | 3,682,040 (1.14%) |

As a majority of the votes were cast in favour of each of the resolutions numbered 1 to 10, these resolutions were duly passed as ordinary resolutions.

As more than two-thirds of the votes were cast in favour of the resolutions numbered 11 to 13, these resolutions were duly passed as special resolutions.

By Order of the Board
**TransThera Sciences (Nanjing), Inc.**
**藥捷安康（南京）科技股份有限公司**
**Dr. Frank Wu**
*Chairman and Chief Executive Officer*

Hong Kong, 4 August 2025

*As at the date of this announcement, the Board comprises Dr. Frank Wu and Mr. Wu Di as executive Directors; Ms. Jia Zhongxin and Dr. Yi Hua as non-executive Directors; and Ms. Chui Hoi Yam, Ms. Zheng Zhelan and Mr. Li Shu Pai as independent non-executive Directors.*